➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
Moodys
McKesson
Merck

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Remimazolam


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Remimazolam?

Remimazolam is an investigational drug.

There have been 18 clinical trials for Remimazolam. The most recent clinical trial was a Phase 3 trial, which was initiated on June 28th 2018.

The most common disease conditions in clinical trials are Substance-Related Disorders and [disabled in preview]. The leading clinical trial sponsors are Paion UK Ltd., Jiangsu HengRui Medicine Co., Ltd., and PRA Health Sciences.

There are twenty-two US patents protecting this investigational drug and one hundred and twenty-six international patents.

Recent Clinical Trials for Remimazolam
TitleSponsorPhase
A Clinical Study of Remimazolam Tosilate in Patients Undergoing BronchoscopyJiangsu HengRui Medicine Co., Ltd.Phase 3
A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective SurgeryJiangsu HengRui Medicine Co., Ltd.Phase 3
Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective SurgeryCreative Clinical Research GmbHPhase 3

See all Remimazolam clinical trials

Clinical Trial Summary for Remimazolam

Top disease conditions for Remimazolam
Top clinical trial sponsors for Remimazolam

See all Remimazolam clinical trials

US Patents for Remimazolam

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Remimazolam   Start Trial Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-A][1,4]benzodiaze- pine-4-yl]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process PAION UK LIMITED (Cambridge, Cambridgeshire, GB)   Start Trial
Remimazolam   Start Trial Dosing regimen for sedation with CNS 7056 (remimazolam) PAION UK LTD. (Histon Cambridge, GB)   Start Trial
Remimazolam   Start Trial Dosing regimen for sedation with CNS 7056 (Remimazolam) PAION UK LTD. (Histon, Cambridge, unknown)   Start Trial
Remimazolam   Start Trial Dosing regimen for sedation with CNS 7056 (Remimazolam) PAION UK LTD. (Histon, Cambridge, GB)   Start Trial
Remimazolam   Start Trial Process for preparing 3-[(S)-7-bromo-2-((2-oxopropyl)amino)-5-pyridin-2-yl-3H-1,4-benzodiazepin- -3-yl]propionic acid methyl ester Paion UK Limited (Cambridge Cambridgeshire, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Remimazolam

Drugname Country Document Number Estimated Expiration Related US Patent
Remimazolam Australia 2010294873 2029-09-18   Start Trial
Remimazolam Canada 2774018 2029-09-18   Start Trial
Remimazolam China 102753525 2029-09-18   Start Trial
Remimazolam Denmark 2477967 2029-09-18   Start Trial
Remimazolam European Patent Office 2305647 2029-09-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Johnson and Johnson
Harvard Business School
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.